Dr. Lei Cao, The First Affiliated Hospital of Nanjing Medical University, China.
Dr. Lei Cao 🎓, Deputy Chief Physician, Master’s Supervisor, and Lecturer at The First Affiliated Hospital of Nanjing Medical University, specializes in malignant lymphomas and lymphoproliferative disorders 🔬. She has led multiple national research projects, published in top-tier journals 📚, and received prestigious awards and scholarships 🏅. With a strong focus on individualized treatment and prognostic stratification, Dr. Cao is advancing cancer care and research globally 🌍.
Professional Profile
Orcid Profile
🧠 Early Academic Pursuits
Dr. Lei Cao began her academic journey with a passion for hematology and oncology, pursuing rigorous medical education that laid the foundation for her specialization in malignant lymphomas and lymphoproliferative disorders. Her early focus on precise prognostic stratification and individualized treatments set the tone for a career rooted in clinical excellence and scientific inquiry.
💼 Professional Endeavors
Currently serving as Deputy Chief Physician, Master’s Supervisor, and Lecturer at the First Affiliated Hospital of Nanjing Medical University, Dr. Cao is a dynamic force in clinical medicine and medical education. She is actively involved in mentoring graduate students while maintaining a busy clinical and research schedule.
🔬 Contributions and Research Focus On Hematology
Dr. Cao’s research focuses on T-cell, B-cell, NK/T-cell, and Hodgkin lymphomas, with an emphasis on improving patient survival and quality of life through personalized medicine. She has led several national and institutional research projects, notably as Principal Investigator on prestigious grants such as the National Natural Science Foundation of China Youth Project and the Bethune Medical Science Research Foundation.
Her research outputs address topics like immunosuppressive microenvironments, hepatitis B reactivation in lymphoma patients, and novel chemotherapy strategies. She has authored multiple peer-reviewed SCI-indexed journal articles, furthering insights into the biology and treatment of hematologic malignancies
🌍 Impact and Influence
Dr. Cao’s work has directly contributed to clinical protocols, particularly in the treatment of indolent and relapsed lymphomas. Her clinical innovations and data-driven treatment strategies are helping to personalize therapies for patients across China. As a reviewer for journals such as Frontiers in Oncology and Cancer Medicine, she helps maintain the integrity of scientific research globally.
📚 Academic Citations
With a citation index of 419, her work demonstrates growing international recognition, showcasing the impact of her findings on clinical and academic communities alike.
🏆 Awards and Honors
Dr. Lei Cao’s accolades include:
-
🥇 First Prize, 2022 Jiangsu Anti-Cancer Association
-
🥉 Third Prize, 2023 Clinical Research Innovation Award, Jiangsu Ruihua Charity Foundation
-
🌍 Jiangsu Government Study Abroad Scholarships (2020 & 2023)
-
👩🔬 2019 CSCO 35 Under 35 Most Promising Young Oncologist
- 🎓 Multiple National Scholarships
🧪 Patents and Publications
-
📄 Patent: ZL202121517226.0 (National Utility Patent)
-
📰 Authored numerous high-impact publications in journals such as Blood Cancer Journal, British Journal of Haematology, Annals of Medicine, and Cancer Science.
🔮 Legacy and Future Contributions
Looking ahead, Dr. Lei Cao aims to refine stratification models, enhance targeted therapies, and further promote patient-centric care in hematologic malignancies. Her leadership, both in research and mentorship, continues to inspire a new generation of oncologists and researchers. Her future endeavors promise to deepen the scientific understanding of lymphoma biology and expand access to innovative treatments.
📚Publications Top Notes
📘 Title: Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients
📚 Journal: British Journal of Haematology
📅 Year: 2023
🧪🩸🛡️ (Oncology, Haematology, Immunity)
📘 Title: Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma
📚 Journal: Blood Cancer Journal
📅 Year: 2025
🧠🧬💉 (Oncology, Hematology, CNS)